🇺🇸 FDA
Pipeline program

ORIC-114

ORIC-114-01

Phase 2 small_molecule active

Quick answer

ORIC-114 for Solid Tumors is a Phase 2 program (small_molecule) at Oric Pharmaceuticals with 1 ClinicalTrials.gov record(s).

Program details

Company
Oric Pharmaceuticals
Indication
Solid Tumors
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials